R&D

ENDOTHELIAL DYSFUNCTION

ENDOTHELIAL DYSFUNCTION

Vascular endothelial dysfunction is an early pathogenesis factor in cardiovascular disease, consisting of impaired vasodilation, angiogenesis, and barrier dysfunction. Vascular endothelial dysfunction is associated with metabolic diseases such as diabetes, obesity, or metabolic syndrome, which are linked to cardiovascular disease. Oxidative stress and inflammation play a major role in the pathogenesis of blood and endothelial dysfunction.

Vascular endothelial dysfunction is an early pathogenesis factor in cardiovascular disease, consisting of impaired vasodilation, angiogenesis, and barrier dysfunction. Vascular endothelial dysfunction is associated with metabolic diseases such as diabetes, obesity, or metabolic syndrome, which are linked to cardiovascular disease. Oxidative stress and inflammation play a major role in the pathogenesis of blood and endothelial dysfunction.

Endothelial dysfunction in aging & vascular associated diseases

Curacle’s SOLVADYS® Strategy

CURACLE’S Approach

"SPAR: Phenotype-Based Approach & Structure-Phenotypic Activity Relationship"

"SPAR: Phenotype-Based Approach & Structure-Phenotypic Activity Relationship"

Establishment of SPAR

CU06 Development as the first endothelial dysfunction blocker

• CU06, a small molecule endothelial dysfunction blocker developed by SOLVADYS
• High correlation between structure and phenotype activity
• New therapeutic concept for neurovascular and inflammatory diseases

• CU06-1004, a small molecule endothelial dysfunction blocker developed by SOLVADYS
• High correlation between structure and phenotype activity
• New therapeutic concept for neurovascular and inflammatory diseases